Appointments

Yang brings with him over ten years of experience in leading therapeutic oncology products through early-stage clinical development and late-stage global registration trials at both Bristol Myers Squibb and Mersana Therapeutics.

In his previous role at Mersana Therapeutics, Yang oversaw the development of various novel assets both in early-and late-stage global development. Prior to this he spent over a decade at Bristol Myers Squibb in various leadership roles.

Cyrus Mozayeni, chief executive officer of Pheon Therapeutics, stated: “As a seasoned chief medical officer, Dr Yang’s extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company. His deep knowledge of oncology clinical development will be invaluable as we advance our first-in-class ADCs for the treatment of solid tumours.”

Commenting on his new role, Yang added: “Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumours. We are now preparing to transition into clinical development and are working diligently to improve outcomes for patients facing hard-to-treat cancers."